| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2010 , Vol 52 , Num 2
EFFECT OF ROSIGLITAZONE ON THE NICOTINAMIDE-STREPTOZOTOCIN INDUCED TYPE-2 DIABETES MELLITUS MEDIATED DEFECTS IN SPERM ABNORMALITIES AND OXIDATIVE DEFENSE SYSTEM IN MALE WISTAR RATS
Department of Pharmacology Al-Ameen College Of Pharmacy, Opp. Lalbagh Main Gate, Hosur Road, Bangalore-India
Viewed :
19847
-
Downloaded :
5903
The nuclear damages due to the generation of reactive oxygen species is the leading cause for the male infertility in diabetic patients. Rosiglitazone, a PPAR-γ ligand was tested against the nicotinamide (230 mg/kg) and streptozotocin (65 mg/kg) induced reproductive defects in experimental type-2 diabetes mellitus. Rosiglitazone was tested in two doses (1 and 10 mg/kg, p.o daily for 4 weeks) to evaluate its role on the type-2 diabetes induced changes in the sperm shape and sperm count in rats, besides, estimating the serum antioxidant enzyme levels. The results indicate that administration of rosiglitazone produced a dose-dependent inhibition against the alterations induced by the diabetic condition. At 10 mg/kg, rosiglitazone significantly (P<0.001) prevented the abnormalities in sperm shape and increased the sperm count, while the lower dose increased (P<0.01) only the sperm count in the diabetic animals. The antioxidant study indicated that administration of rosiglitazone to diabetic animals improves the antioxidant status. These observations suggest that the antioxidant property of rosiglitazone might have contributed for its ability to decrease the type-2 diabetes mediated sperm abnormalities.
Keywords :
ROSIGLITAZONE, SPERM SHAPE ABNORMALITY, SPERM COUNT, ANTIOXIDANT